A nonlinear mixed effects IVIVC model for multi-release drug delivery systems

The purpose of this analysis was the development of an IVIVC model, which involves a convolution step as described by O’Hara et al. and to describe a dual-release system: a controlled release formulation, which contains an initial immediate release element. Four formulations of Galantamine® were used to test this modelling technique and a level A IVIVC, which meets the FDA criteria for internal and external validation, was successfully developed.

[1]  L. Lesko,et al.  Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations. , 1997, Advances in experimental medicine and biology.

[2]  C. Chatfield.  Continuous Univariate Distributions, Vol. 1 , 1995 .

[3]  T. Thomsen,et al.  Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. , 1990, Life sciences.

[4]  G. Wing,et al.  A Primer on Integral Equations of the First Kind: The Problem of Deconvolution and Unfolding , 1987 .

[5]  G. Wilcock,et al.  Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial , 2000, BMJ : British Medical Journal.

[6]  P. Costa,et al.  Modeling and comparison of dissolution profiles. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[7]  L. Wilkins.  Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension , 2000, Neurology.

[8]  N. L. Johnson,et al.  Continuous Univariate Distributions. , 1995 .

[9]  F Langenbucher,et al.  Letters to the Editor: Linearization of dissolution rate curves by the Weibull distribution , 1972, The Journal of pharmacy and pharmacology.

[10]  H. Kewitz.  Pharmacokinetics and metabolism of galanthamine , 1997 .

[11]  J. A. Goldsmith,et al.  On methods of expressing dissolution rate data , 1978, The Journal of pharmacy and pharmacology.

[12]  I. M. Suslova,et al.  Interaction of reversible inhibitors with catalytic centers and allosteric sites of cholinesterases , 1976, Bulletin of Experimental Biology and Medicine.

[13]  E X Albuquerque,et al.  Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. , 1996, Molecular pharmacology.

[14]  W R Gillespie,et al.  Convolution-based approaches for in vivo-in vitro correlation modeling. , 1997, Advances in experimental medicine and biology.

[15]  P. Tariot,et al.  A 5-month, randomized, placebo-controlled trial of galantamine in AD , 2000, Neurology.

[16]  L. Marsh,et al.  Treatment of early Parkinson's disease , 2000, BMJ : British Medical Journal.

[17]  E. Peskind,et al.  Galantamine in AD , 2000, Neurology.

[18]  John Davis,et al.  Deconvolution Based Approach for Level A In Vivo-In Vitro Correlation Modelling: Statistical Considerations , 2005 .

[19]  A. Dunne,et al.  In Vivo–In Vitro Correlation (IVIVC) Modeling Incorporating a Convolution Step , 2001, Journal of Pharmacokinetics and Pharmacodynamics.